Amendment 1 to Sub-License and Collaboration Agreement, dated April 19, 2013, between the Registrant (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated March 20, 2012
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.
David A. Vallo
Senior Protect Manager
One MedImmune Way
Gaithersburg, MD 20878
Bellinzona, April 19, 2013
Re: Sub-License and Collaboration Agreement dated as of March 20, 2012 (Agreement) between MedImmune LLC (MedImmune) and Humabs BioMed SA (Humabs)
Dear Mr. Vallo,
We hereby notify MedImmune of Humabs agreement to extend the scope of the Research Project to work on Klebsiella, which has been elected as the Extra Target in accordance with Section 5.19.2 of the Agreement.
In consideration of the generally increased research costs per FTE at Humabs, we submits to MedImmune the request to increase the amount of Research Funding payments (Section 220.127.116.11. of the Agreement) from [***] of the Research Term.
Thank you for your time and cooperation. We also continue to look forward to a successful collaboration with MedImmune.
/s/ Alcide Barberis
Alcide Barberis, PhD
President and CEO
Humabs BioMed SA
Via Mirasole 1
CH-6500 Bellinzona, Switzerland